PURPOSE: Patient reported outcomes (PROs) are an optimal method for assessing quality of life (QOL), including physical and psychosocial health. This review summarizes PROs frequently assessed in the setting of a DCIS diagnosis. RECENT FINDINGS: Health-related QOL has generally been found to be modestly affected in women with DCIS and similar to women with invasive breast cancer. Several studies reported a substantial negative impact on sexual health and body image, including some differences based on surgery type. Some patients experience pain after treatment, although many physical symptoms resolve. The prevalence of anxiety and depression varied based on assessment timing, with symptoms improving over time. Women with DCIS often overestimate the risks associated both with DCIS and invasive cancer. SUMMARY: PROs provide critical information regarding the experiences of women following a DCIS diagnosis. Continued inclusion of PROs in clinical trials is warranted, further informing treatment decisions and adequately preparing patients for what to expect following treatment.
PURPOSE: Patient reported outcomes (PROs) are an optimal method for assessing quality of life (QOL), including physical and psychosocial health. This review summarizes PROs frequently assessed in the setting of a DCIS diagnosis. RECENT FINDINGS: Health-related QOL has generally been found to be modestly affected in women with DCIS and similar to women with invasive breast cancer. Several studies reported a substantial negative impact on sexual health and body image, including some differences based on surgery type. Some patients experience pain after treatment, although many physical symptoms resolve. The prevalence of anxiety and depression varied based on assessment timing, with symptoms improving over time. Women with DCIS often overestimate the risks associated both with DCIS and invasive cancer. SUMMARY: PROs provide critical information regarding the experiences of women following a DCIS diagnosis. Continued inclusion of PROs in clinical trials is warranted, further informing treatment decisions and adequately preparing patients for what to expect following treatment.
Authors: Adele Francis; Jeremy Thomas; Lesley Fallowfield; Matthew Wallis; John M S Bartlett; Cassandra Brookes; Tracy Roberts; Sarah Pirrie; Claire Gaunt; Jennie Young; Lucinda Billingham; David Dodwell; Andrew Hanby; Sarah E Pinder; Andrew Evans; Malcolm Reed; Valerie Jenkins; Lucy Matthews; Maggie Wilcox; Patricia Fairbrother; Sarah Bowden; Daniel Rea Journal: Eur J Cancer Date: 2015-08-18 Impact factor: 9.162
Authors: Eileen Rakovitch; Sharon Nofech-Mozes; Wedad Hanna; Rinku Sutradhar; Frederick L Baehner; Dave P Miller; Cindy Fong; Sumei Gu; Alan Tuck; Sandip Sengupta; Leela Elavathil; Prashant A Jani; Michel Bonin; Martin C Chang; Elzbieta Slodkowska; Joseph M Anderson; Diana B Cherbavaz; Steven Shak; Lawrence Paszat Journal: J Natl Cancer Inst Date: 2017-04-01 Impact factor: 13.506
Authors: Vicki Hart; Brian L Sprague; Susan G Lakoski; John M Hampton; Polly A Newcomb; Ronald E Gangnon; Amy Trentham-Dietz Journal: J Clin Oncol Date: 2016-02-16 Impact factor: 44.544
Authors: Aparna R Parikh; Celia Patricia Kaplan; Nancy J Burke; Jennifer Livaudais-Toman; E Shelley Hwang; Leah S Karliner Journal: Breast Cancer Res Treat Date: 2013-09-01 Impact factor: 4.624